Welcome to Archaea Biology and Ecogenomics

Department of Functional and Evolutionary Ecology

We belong to the Faculty of Life Sciences of the University of Vienna. On 1 January 2022 Archaea Biology, Molecular Systems Biology, Limnology and Bio-Oceanography and Marine Biology merged to the Department of Functional and Evolutionary Ecology.

Archaea arose together with Bacteria as the first organisms on this planet about 3.5 billion years ago. They form a separate domain of life beside bacteria and eukaryotes and inhabit virtually all environments on earth, including the most extreme environments that can sustain life.
Our unit studies the biology of archaea as well as bacterial symbioses with a focus on ecological, physiological and evolutionary aspects to shed light on the diversity and fundamental distinctions between these two prokaryotic groups.

In particular we are interested in:

- the ecological distribution of archaea from terrestrial, aquatic and hot environments

- the phylogeny of archaea

- the metabolism and genomes of ammonia oxidizing thaumarchaeota

- virus-defense (CRISPR-) systems of hyperthermophilic archaea

- archaea Biotechnology

- bacterium-nematode symbioses

We thus attempt to improve the understanding of the role of microorganisms, in particular of archaea, in global biogeochemical cycles and in early evolution.

15.03.2024
 

"Exploring the effects of biological nitrification inhibitors in the soil microbial communities"

12.03.2024
 

"Crucial steps in evolution: The rise of genome architecture"

10.03.2024
 

"Aua - heiß! Lebt da jemand im Vulkan?"

08.03.2024
 

"The Environment and Climate Research Hub (ECH)"

28.02.2024
 

"A genome-scale metabolic model for the archaeon Nitrososphaera viennensis"

28.02.2024
 

"Extreme habitats on earth - thriving at the limits of life"

Guest Lectures

09.04.2024
 

"How evolutionary interplay between sexes can help us define phenotypes and develop drugs"

26.03.2024
 

"Biomechanics of Muscle Morphogenesis"

19.03.2024
 

"Dissimilar microbiome organization demarcates pulmonary exacerbation types and impacts treatment outcome in cystic fibrosis"